Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088832 | 0.87 | DRD4 (0.54) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL829177 | 0.79 | AR (0.65) | DRD4DRD2GRM5ARHTR1A | |
| SCHEMBL30406641 | 0.79 | AR (0.59) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL2321072 | 0.79 | DRD4 (0.49) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL23277098 | 0.78 | KDM4E (0.58) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL20156847 | 0.78 | DRD4 (0.51) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL2077260 | 0.78 | GRM5 (0.51) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL21572676 | 0.78 | DRD4 (0.48) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL2077261 | 0.78 | ADRA2C (0.56) | DRD4DRD2GRM5ARDRD3 | |
| SCHEMBL8760562 | 0.78 | DRD2 (0.43) | DRD4DRD2GRM5ARDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD4 139/4885DRD2 187/4885GRM5 378/4885 |
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | DRD4 3112/4885DRD2 3770/4885GRM5 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.